
pmid: 27206757
Chronic pruritus is a distressing symptom that is often refractory to treatment. Patients frequently fail topical therapies and oral over-the-counter antihistamines, prompting the clinician to consider alternative therapies such as neuroactive agents. Herein, the use of gabapentin and pregabalin, 2 medications well known for treating neuropathic pain and epilepsy that are occasionally used for relieving chronic pruritus is explored. The findings from original sources published to date to evaluate the use of gabapentin and pregabalin as antipruritic agents are explored. They are found to be promising alternative treatments for the relief of several forms of chronic pruritus, particularly uremic pruritus and neuropathic or neurogenic itch, in patients who fail conservative therapies.
Male, Cyclohexanecarboxylic Acids, Pruritus, Pregabalin, Risk Assessment, Severity of Illness Index, Treatment Outcome, Anti-Anxiety Agents, Patient Satisfaction, Chronic Disease, Quality of Life, Humans, Female, Amines, Gabapentin, gamma-Aminobutyric Acid
Male, Cyclohexanecarboxylic Acids, Pruritus, Pregabalin, Risk Assessment, Severity of Illness Index, Treatment Outcome, Anti-Anxiety Agents, Patient Satisfaction, Chronic Disease, Quality of Life, Humans, Female, Amines, Gabapentin, gamma-Aminobutyric Acid
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 120 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 1% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
